622 related articles for article (PubMed ID: 27567356)
1. Outcomes of Elderly Patients Who Receive Combined Modality Therapy for Locally Advanced Non-Small-Cell Lung Cancer.
Zaki M; Dominello M; Dyson G; Gadgeel S; Wozniak A; Miller S; Paximadis P
Clin Lung Cancer; 2017 Jan; 18(1):e21-e26. PubMed ID: 27567356
[TBL] [Abstract][Full Text] [Related]
2. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
3. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
Garg S; Gielda BT; Kiel K; Turian JV; Fidler MJ; Batus M; Bonomi P; Sher DJ
Pract Radiat Oncol; 2014; 4(5):342-348. PubMed ID: 25194104
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery.
Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH
Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175
[TBL] [Abstract][Full Text] [Related]
5. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of lymphovascular invasion on biopsy specimens in lung cancer treated with definitive chemoradiotherapy.
Massabeau C; Filleron T; Wakil G; Rouquette I; Bachaud JM; Leguellec S; Delisle MB; Toulas C; Mazieres J; Cohen-Jonathan Moyal E
Clin Lung Cancer; 2012 Jan; 13(1):59-67. PubMed ID: 21856239
[TBL] [Abstract][Full Text] [Related]
7. Improved survival associated with neoadjuvant chemoradiation in patients with clinical stage IIIA(N2) non-small-cell lung cancer.
Koshy M; Fedewa SA; Malik R; Ferguson MK; Vigneswaran WT; Feldman L; Howard A; Abdelhady K; Weichselbaum RR; Virgo KS
J Thorac Oncol; 2013 Jul; 8(7):915-22. PubMed ID: 23608815
[TBL] [Abstract][Full Text] [Related]
8. Early Weight Loss during Chemoradiotherapy Has a Detrimental Impact on Outcome in NSCLC.
Sanders KJ; Hendriks LE; Troost EG; Bootsma GP; Houben RM; Schols AM; Dingemans AM
J Thorac Oncol; 2016 Jun; 11(6):873-9. PubMed ID: 26940529
[TBL] [Abstract][Full Text] [Related]
9. Non small cell lung cancer in the elderly: clinico-pathologic, management and outcome characteristics in comparison to younger patients.
Koumarianou A; Fountzilas G; Kosmidis P; Klouvas G; Samantas E; Kalofonos C; Pentheroudakis G; Economopoulos T; Pectasides D
J Chemother; 2009 Nov; 21(5):573-83. PubMed ID: 19933050
[TBL] [Abstract][Full Text] [Related]
10. Matched-Pair Analysis of High Dose Versus Standard Dose Definitive Chemoradiation for Locally Advanced Non-Small-Cell Lung Cancer.
Johnson MD; Sura K; Mangona VS; Glick A; Wallace M; Ye H; Grills IS
Clin Lung Cancer; 2017 Mar; 18(2):149-155. PubMed ID: 27426973
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
12. Induction chemoradiotherapy followed by surgical resection for clinical T3 or T4 locally advanced non-small cell lung cancer.
Shien K; Toyooka S; Kiura K; Matsuo K; Soh J; Yamane M; Oto T; Takemoto M; Date H; Miyoshi S
Ann Surg Oncol; 2012 Aug; 19(8):2685-92. PubMed ID: 22396006
[TBL] [Abstract][Full Text] [Related]
13. Phase 2 study of pemetrexed plus carboplatin, or pemetrexed plus cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer.
Choy H; Schwartzberg LS; Dakhil SR; Garon EB; Gerber DE; Choksi JK; Govindan R; Peng G; Koustenis A; Treat J; Obasaju C
J Thorac Oncol; 2013 Oct; 8(10):1308-16. PubMed ID: 23981966
[TBL] [Abstract][Full Text] [Related]
14. Timing of Surgery after Neoadjuvant Chemoradiation in Locally Advanced Non-Small Cell Lung Cancer.
Gao SJ; Corso CD; Wang EH; Blasberg JD; Detterbeck FC; Boffa DJ; Decker RH; Kim AW
J Thorac Oncol; 2017 Feb; 12(2):314-322. PubMed ID: 27720827
[TBL] [Abstract][Full Text] [Related]
15. S-1 plus cisplatin with concurrent radiotherapy versus cisplatin alone with concurrent radiotherapy for stage III non-small cell lung cancer: a pilot randomized controlled trial.
Yao L; Xu S; Xu J; Yang C; Wang J; Sun D
Radiat Oncol; 2015 Jan; 10():10. PubMed ID: 25572571
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
17. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Chen KY; Chen JH; Shih JY; Yang CH; Yu CJ; Yang PC
J Thorac Oncol; 2010 Jan; 5(1):82-9. PubMed ID: 19884854
[TBL] [Abstract][Full Text] [Related]
18. Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.
Speirs CK; DeWees TA; Rehman S; Molotievschi A; Velez MA; Mullen D; Fergus S; Trovo M; Bradley JD; Robinson CG
J Thorac Oncol; 2017 Feb; 12(2):293-301. PubMed ID: 27743888
[TBL] [Abstract][Full Text] [Related]
19. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).
Katakami N; Tada H; Mitsudomi T; Kudoh S; Senba H; Matsui K; Saka H; Kurata T; Nishimura Y; Fukuoka M
Cancer; 2012 Dec; 118(24):6126-35. PubMed ID: 22674529
[TBL] [Abstract][Full Text] [Related]
20. Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada.
Vinod SK; Wai E; Alexander C; Tyldesley S; Murray N
J Thorac Oncol; 2012 Jul; 7(7):1155-63. PubMed ID: 22617240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
